Anti-PD-1 Therapy Selection Using Inflammatory Gene Signatures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy approaches, such as those using PD-1/PD-L1 inhibitors, have variable effectiveness due to individual patient characteristics, necessitating targeted strategies to identify suitable candidates for treatment.
Innovation Solution
A method involving the identification of patients with high inflammatory signature scores and tumor mutation burden (TMB) status of at least 10 mutations per megabase, using an inflammatory gene panel comprising CD274 (PD-L1), CD8A, and STAT1, to determine suitability for anti-PD-1 antibody treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If anti-PD-1 antibody treatment is administered to all cancer patients, then treatment accessibility is improved, but treatment effectiveness decreases due to variable patient response
Solution Approach 1:
The patent applies local quality by identifying specific patient subgroups with distinct molecular characteristics (high inflammatory signature score and high TMB) who are most likely to respond to anti-PD-1 therapy. This allows the treatment to be optimized for specific local patient populations rather than applied uniformly to all cancer patients, thereby improving overall treatment effectiveness.
Solution Approach 2:
The patent utilizes parameter changes by establishing specific threshold values for inflammatory signature score and tumor mutation burden that define the optimal patient population for treatment. By changing the selection criteria based on these measurable parameters, the treatment can be directed at patients with the highest probability of response, improving effectiveness while managing adaptability constraints.
2Measurement precision
If patient identification criteria are made more specific, then treatment precision is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the patient selection process into two independent, measurable components: inflammatory signature score (based on gene expression) and tumor mutation burden (based on genomic sequencing). This segmentation allows each parameter to be assessed separately using established methods, achieving precise patient selection without requiring a single complex diagnostic system.
Solution Approach 2:
The patent uses intermediary markers (inflammatory signature score and TMB) as mediators between the complex biological reality of tumor immunology and the practical needs of patient selection. These intermediaries provide quantifiable, measurable criteria that bridge the gap between basic science and clinical application, enabling precise patient identification through relatively straightforward diagnostic assays.
Data Source
AI summary
The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or anti-gen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score and a tumor that has a high tumor mutation burden (TMB) status. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.